Evidence map›Paper›PMID 33887067›Full record

ArticleGlia2021

The thrombin receptor modulates astroglia-neuron trophic coupling and neural repair after spinal cord injury.

Ha Neui Kim, Erin M Triplet, Maja Radulovic, Samantha Bouchal, Laurel S Kleppe, Whitney L Simon, Hyesook Yoon, Isobel A Scarisbrick

Open access · greenAbstract read
In one paragraph

Article in Glia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Regional Molecular Diversity in Chronic Spinal Cord Injury.Cellular and molecular neurobiology · 2026
    Article
  3. Article
  4. Article
  5. Delayed atorvastatin delivery promotes recovery after experimental spinal cord injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Catalpol as a Component ofFrontiers in pharmacology · 2022
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ha Neui KimDepartment of Physical Medicine and Rehabilitation, Rehabilitation Medicine Research Center, Rochester, Minnesota, USA.ORCID 0000-0002-5651-4727
Erin M TripletDepartment of Physical Medicine and Rehabilitation, Rehabilitation Medicine Research Center, Rochester, Minnesota, USA.ORCID 0000-0002-5303-4576
Maja RadulovicDepartment of Physical Medicine and Rehabilitation, Rehabilitation Medicine Research Center, Rochester, Minnesota, USA.
Samantha BouchalDepartment of Physical Medicine and Rehabilitation, Rehabilitation Medicine Research Center, Rochester, Minnesota, USA.
Laurel S KleppeDepartment of Physical Medicine and Rehabilitation, Rehabilitation Medicine Research Center, Rochester, Minnesota, USA.
Whitney L SimonDepartment of Physical Medicine and Rehabilitation, Rehabilitation Medicine Research Center, Rochester, Minnesota, USA.
Hyesook YoonDepartment of Physical Medicine and Rehabilitation, Rehabilitation Medicine Research Center, Rochester, Minnesota, USA.
Isobel A ScarisbrickDepartment of Physical Medicine and Rehabilitation, Rehabilitation Medicine Research Center, Rochester, Minnesota, USA.ORCID 0000-0003-2395-589X
Mayo Clinic · USUniversity of Minnesota Rochester · US

Funding

Medical Scientist Traning Program at Mayo ClinicT32GM065841 · NIGMS · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, SCHIMMENTI, LISA A · 2003 to 2022
$5.8M
Role of Protease Activated Receptors in Spinal Cord Injury and RepairR01NS052741 · NINDS · MAYO CLINIC ROCHESTER · PI SCARISBRICK, ISOBEL A · 2008 to 2017
$3.6M
Targeting Protease Activated Receptor 1 for Repair of the Injured Spinal CordR01NS120877 · NINDS · MAYO CLINIC ROCHESTER · PI SCARISBRICK, ISOBEL A · 2021 to 2024
$1.9M
Targeting Protease Activated Receptor 1 for Repair of the Injured Spinal CordR56NS114117 · NINDS · MAYO CLINIC ROCHESTER · PI SCARISBRICK, ISOBEL A · 2020 to 2020
$542k
Regulatory Action of Protease Activated Receptor 1 in Myelin ProductionR21NS107946 · NINDS · MAYO CLINIC ROCHESTER · PI SCARISBRICK, ISOBEL A · 2019 to 2019
$437k
NIGMS NIH HHS T32 GM065841NINDS NIH HHS R01 NS052741NINDS NIH HHS R01 NS120877NINDS NIH HHS R21 NS107946NINDS NIH HHS R56 NS114117
6 · The paper itself

Abstract

Excessive activation of the thrombin receptor, protease activated receptor 1 (PAR1) is implicated in diverse neuropathologies from neurodegenerative conditions to neurotrauma. PAR1 knockout mice show improved outcomes after experimental spinal cord injury (SCI), however information regarding the underpinning cellular and molecular mechanisms is lacking. Here we demonstrate that genetic blockade of PAR1 in female mice results in improvements in sensorimotor co-ordination after thoracic spinal cord lateral compression injury. We document improved neuron preservation with increases in Synapsin-1 presynaptic proteins and GAP43, a growth cone marker, after a 30 days recovery period. These improvements were coupled to signs of enhanced myelin resiliency and repair, including increases in the number of mature oligodendrocytes, their progenitors and the abundance of myelin basic protein. These significant increases in substrates for neural recovery were accompanied by reduced astrocyte (Serp1) and microglial/monocyte (CD68 and iNOS) pro-inflammatory markers, with coordinate increases in astrocyte (S100A10 and Emp1) and microglial (Arg1) markers reflective of pro-repair activities. Complementary astrocyte-neuron co-culture bioassays suggest astrocytes with PAR1 loss-of-function promote both neuron survival and neurite outgrowth. Additionally, the pro-neurite outgrowth effects of switching off astrocyte PAR1 were blocked by inhibiting TrkB, the high affinity receptor for brain derived neurotrophic factor. Altogether, these studies demonstrate unique modulatory roles for PAR1 in regulating glial-neuron interactions, including the capacity for neurotrophic factor signaling, and underscore its position at neurobiological intersections critical for the response of the CNS to injury and the capacity for regenerative repair and restoration of function.

Indexed as

Receptor, PAR-1Spinal Cord InjuriesAnimalsAstrocytesFemaleMiceNeuronsReceptors, ThrombinSpinal CordReceptor, PAR-1Receptors, Thrombinastrogliabrain derived neurotrophic factorgrowth conemyelinprotease activated receptor 1spinal cord traumasynapseTrkB

Identifiers

PMID33887067
PMCPMC8672305
OpenAlexW3154490924

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.